Literature DB >> 6246177

Cell-mediated immunity to varicella-zoster virus after allogeneic marrow transplant.

J D Meyers, N Flournoy, E D Thomas.   

Abstract

The cellular immune response of normal persons and marrow transplant recipients to varicella-zoster virus (VZV) antigen was measured with use of the lymphocyte transformation response. Ninety-nine of 100 normal persons with previous VZV infection had a stimulation index of greater than or equal to 4.8, while 10 susceptible persons had responses of less than or equal to 3.0. Before transplant, responses were lower than normal in patients with leukemia in relapse (P = 0.001), but not in patients with leukemia in remission or with aplastic anemia. Throughout the first 100 days after transplant, lymphocyte response was depressed (P less than 0.0005), especially among recipients of antithymocyte globulin during days 41-80 (P less than 0.05). Patients with aplastic anemia had higher responses than those with leukemia during days 20-60 (P less than 0.02). By one year, most responses were normal. Long-term survivors who had recurrent VZV infection had positive responses more often than those without recurrent infection (P = 0.01). The lymphocyte response to VZV antigen parelleled, and thus may predict, periods of increased susceptibility to VZV infection.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6246177     DOI: 10.1093/infdis/141.4.479

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

1.  Varicella-zoster virus glycoproteins B and E are major targets of CD4+ and CD8+ T cells reconstituting during zoster after allogeneic transplantation.

Authors:  Patrick Kleemann; Eva Distler; Eva M Wagner; Simone Thomas; Sebastian Klobuch; Steffi Aue; Elke Schnürer; Hansjörg Schild; Matthias Theobald; Bodo Plachter; Stefan Tenzer; Ralf G Meyer; Wolfgang Herr
Journal:  Haematologica       Date:  2011-12-29       Impact factor: 9.941

2.  Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial.

Authors:  Adriana Bastidas; Javier de la Serna; Mohamed El Idrissi; Lidia Oostvogels; Philippe Quittet; Javier López-Jiménez; Filiz Vural; David Pohlreich; Tsila Zuckerman; Nicolas C Issa; Gianluca Gaidano; Je-Jung Lee; Sunil Abhyankar; Carlos Solano; Jaime Perez de Oteyza; Michael J Satlin; Stefan Schwartz; Magda Campins; Alberto Rocci; Carlos Vallejo Llamas; Dong-Gun Lee; Sen Mui Tan; Anna M Johnston; Andrew Grigg; Michael J Boeckh; Laura Campora; Marta Lopez-Fauqued; Thomas C Heineman; Edward A Stadtmauer; Keith M Sullivan
Journal:  JAMA       Date:  2019-07-09       Impact factor: 56.272

3.  Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study.

Authors:  Michael Boeckh; Hyung W Kim; Mary E D Flowers; Joel D Meyers; Raleigh A Bowden
Journal:  Blood       Date:  2005-11-10       Impact factor: 22.113

4.  Reduced cellular immunity to varicella zoster virus during treatment for acute lymphoblastic leukemia of childhood: in vitro studies of possible mechanisms.

Authors:  R H Giller; R A Bowden; M J Levin; L J Walker; D G Tubergen; A R Hayward
Journal:  J Clin Immunol       Date:  1986-11       Impact factor: 8.317

5.  Lysis of varicella zoster virus infected cells by lymphocytes from normal humans and immunosuppressed pediatric leukaemic patients.

Authors:  R A Bowden; M J Levin; R H Giller; D G Tubergen; A R Hayward
Journal:  Clin Exp Immunol       Date:  1985-05       Impact factor: 4.330

Review 6.  Varicella-zoster virus.

Authors:  A M Arvin
Journal:  Clin Microbiol Rev       Date:  1996-07       Impact factor: 26.132

7.  Donor and recipient origin of herpesvirus-reactive lymphocytes after bone marrow transplantation. Brief report.

Authors:  P Ljungman; G Gahrton; O Ringdén; B Wahren
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

Review 8.  Postherpetic neuralgia in the cancer patient.

Authors:  E Lojeski; R A Stevens
Journal:  Curr Rev Pain       Date:  2000

9.  Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice.

Authors:  Edward A Stadtmauer; Keith M Sullivan; Mohamed El Idrissi; Bruno Salaun; Aránzazu Alonso Alonso; Charalambos Andreadis; Veli-Jukka Anttila; Adrian Jc Bloor; Raewyn Broady; Claudia Cellini; Antonio Cuneo; Alemnew F Dagnew; Emmanuel Di Paolo; HyeonSeok Eom; Ana Pilar González-Rodríguez; Andrew Grigg; Andreas Guenther; Thomas C Heineman; Isidro Jarque; Jae-Yong Kwak; Alessandro Lucchesi; Lidia Oostvogels; Marta Polo Zarzuela; Anne E Schuind; Thomas C Shea; Ulla Marjatta Sinisalo; Filiz Vural; Lucrecia Yáñez San Segundo; Pierre Zachée; Adriana Bastidas
Journal:  Hum Vaccin Immunother       Date:  2021-08-18       Impact factor: 3.452

Review 10.  Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials.

Authors:  Marta López-Fauqued; Maribel Co-van der Mee; Adriana Bastidas; Pierre Beukelaers; Alemnew F Dagnew; Juan Jose Fernandez Garcia; Anne Schuind; Fernanda Tavares-da-Silva
Journal:  Drug Saf       Date:  2021-06-11       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.